<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ERGOTAMINE- ergotamine tartrate and caffeineÂ tablet, film coatedÂ </strong><br>West-Ward Pharmaceutical Corp<br></p></div>
<h1>Ergotamine Tartrate and Caffeine</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">ERGOTAMINE TARTRATE AND CAFFEINE</span><span class="Bold"><br>TABLETS, USP</span><span class="Bold"><br>1MG/100 MG</span></p>
<p>Rev. 11/04Rx Only</p>
</div>
<div class="Warning">
<a name="section-2"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">WARNING</span><br></p>
<p><span class="Bold">Serious and/or life-threatening <span class="product-label-link" type="condition" conceptid="4124836" conceptname="Peripheral ischemia">peripheral ischemia</span> has been associated with the </span><span class="Bold">coadministration</span><span class="Bold"> of ergotamine </span><span class="Bold">tartrate</span><span class="Bold"> and caffeine with potent CYP 3A4 inhibitors including protease inhibitors and </span><span class="Bold">macrolide</span><span class="Bold"> antibiotics. Because CYP 3A4 inhibition elevates the serum levels of ergotamine </span><span class="Bold">tartrate</span><span class="Bold"> and caffeine, the risk for <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> leading to <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span> and/or <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> of the extremities is increased. Hence, concomitant use of these medications is contraindicated. (See also </span><a href="#_CONTRAINDICATIONS">CONTRAINDICATIONS</a><span class="Bold"> and </span><a href="#_WARNINGS">WARNINGS</a><span class="Bold"> sections)</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1><span class="Bold">DESCRIPTION:</span></h1>
<p class="First">Ergotamine Tartrate and Caffeine Tablets USP</p>
<p>ergotamine tartrate USP . . . . . . . . . . . . . . . . . .1 mg</p>
<p>caffeine USP . . . . . . . . . . . . . . . . . . . . . . . . . . .100 mg</p>
<p>In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, compressible sugar, corn starch, magnesium stearate, mannitol, microcrystalline cellulose, sodium starch glycolate, sugar, and tartaric acid. Polishing and Film Coating Solutions may contain the following: FD&amp;C Blue Lake #2, FD&amp;C Yellow Lake #6, hydroxypropyl methylcellulose, polyethylene glycol, and titanium dioxide. The printing ink contains: amide resin, black pigment, natural resin, and wax.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1><span class="Bold">CLINICAL PHARMACOLOGY</span></h1>
<p class="First">Ergotamine is an alpha adrenergic blocking agent with a direct stimulating effect on the smooth muscle of peripheral and cranial blood vessels and produces <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of central vasomotor centers. The compound also has the properties of serotonin antagonism. In comparison to hydrogenated ergotamine, the adrenergic blocking actions are less pronounced and vasoconstrictive actions are greater.</p>
<p>Caffeine, also a cranial vasoconstrictor, is added to further enhance the vasoconstrictive effect without the necessity of increasing ergotamine dosage.</p>
<p>Many <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> patients experience excessive <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> during attacks, making it impossible for them to retain any oral medication. In such cases, therefore, the only practical means of medication is through the rectal route where medication may reach the cranial vessels directly, evading the splanchnic vasculature and the liver.</p>
<p>Pharmacokinetics: Interactions</p>
<p><span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">Pharmacokinetic interactions</span> (increased blood levels of ergotamine) have been reported in patients treated orally with ergotamine and macrolide antibiotics (e.g., troleandomycin, clarithromycin, erythromycin), and in patients treated orally with ergotamine and protease inhibitors (e.g. ritonavir) presumably due to inhibition of cytochrome P450 3A metabolism of ergotamine (see <a href="#s9">CONTRAINDICATIONS</a>). Ergotamine has also been shown to be an inhibitor of cytochrome P450 3A catalyzed reactions. No <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> involving other cytochrome P450 isoenzymes are known.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1><span class="Bold">INDICATIONS AND USAGE</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1"></a><p></p>
<h2>
<span class="Bold">Ergotamine </span><span class="Bold">Tartrate</span><span class="Bold"> and Caffeine</span>
</h2>
<p class="First">Indicated as therapy to abort or prevent <span class="product-label-link" type="condition" conceptid="4134454" conceptname="Vascular headache">vascular headache</span>, e.g., <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> variants or so-called â€œhistaminic cephalalgiaâ€?.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="_CONTRAINDICATIONS"></a><a name="section-5"></a><p></p>
<h1><span class="Bold">CONTRAINDICATIONS</span></h1>
<p class="First">Coadministration of ergotamine with potent CYP 3A4 inhibitors (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, and troleandomycin) has been associated with acute ergot toxicity (<span class="product-label-link" type="condition" conceptid="4201303" conceptname="Ergotism">ergotism</span>) characterized by <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> and <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> of the extremities (see <a href="#_Drug_Interactions">PRECAUTIONS: Drug Interactions</a>), with some cases resulting in amputation. There have been rare reports of <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span> in patients on protease inhibitor therapy when ergotamine tartrate and caffeine was coadministered, at least one resulting in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Because of the increased risk for <span class="product-label-link" type="condition" conceptid="4201303" conceptname="Ergotism">ergotism</span> and other serious vasospastic adverse events, ergotamine use is contraindicated with these drug and other potent inhibitors of CYP 3A4 (e.g., ketoconazole, itraconazole) (see <a href="#_CYP_3A4_Inhibitors">WARNINGS: CYP 3A4 Inhibitors</a>).</p>
<p>Ergotamine tartrate and caffeine may cause fetal harm when administered to pregnant women. Ergotamine tartrate and caffeine is contraindicated in women who are or may become pregnant. If this drug is used during pregnancy or if the patient becomes pregnant while taking this product, the patient should be apprised of the potential hazard to the fetus.</p>
<p><span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">Peripheral vascular disease</span>, coronary heart disease, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, impaired hepatic or renal function and <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any of the components.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="_WARNINGS"></a><a name="section-6"></a><p></p>
<h1><span class="Bold">WARNINGS</span></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="_CYP_3A4_Inhibitors"></a><a name="section-6.1"></a><p></p>
<h2>
<span class="Bold">CYP 3A4 Inhibitors (e.g. </span><span class="Bold">Macrolide</span><span class="Bold"> Antibiotics and Protease Inhibitors)</span>
</h2>
<p class="First">Coadministration of ergotamine with potent CYP 3A4 inhibitors such as protease inhibitors or macrolide antibiotics has been associated with serious adverse events, for this reason, these drugs should not be given concomitantly with ergotamine (see <a href="#s9">CONTRAINDICATIONS</a>). While these reactions have not been reported with less potent CYP 3A4 inhibitors, there is a potential risk for serious toxicity including <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> when these drugs are used with ergotamine. Examples of less potent CYP 3A4 inhibitors include: saquinavir, nefazodone, fluconazole, fluoxetine, grapefruit juice, fluvoxamine, zileuton, metronidazole, and clotrimazole. These lists are not exhaustive, and the prescriber should consider the effects on CYP3A4 of other agents being considered for concomitant use with ergotamine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2><span class="Bold">Fibrotic Complications</span></h2>
<p class="First">There have been a few reports of patients on ergotamine tartrate and caffeine therapy developing retroperitoneal and/or pleuropulmonary <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span>. There have also been rare reports of fibrotic thickening of the aortic, mitral, tricuspid, and/or pulmonary valves with long-term continuous use of ergotamine tartrate and caffeine. Ergotamine tartrate should not be used for chronic daily administration (see <a href="#_DOSAGE_AND_ADMINISTRATION">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="_PRECAUTIONS"></a><a name="section-7"></a><p></p>
<h1><span class="Bold">PRECAUTIONS</span></h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2><span class="Bold">General</span></h2>
<p class="First">Although signs and symptoms of <span class="product-label-link" type="condition" conceptid="4201303" conceptname="Ergotism">ergotism</span> rarely develop even after long term intermittent use of the rectally administered drug, care should be exercised to remain within the limits of recommended dosage.</p>
<p><span class="product-label-link" type="condition" conceptid="4201303" conceptname="Ergotism">Ergotism</span> is manifested by intense arterial <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span>, producing signs and symptoms of peripheral vascular <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>. Ergotamine induces <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span> by a direct action on vascular smooth muscle. In chronic <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> with ergot derivatives, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="442774" conceptname="Intermittent claudication">intermittent claudication</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pains</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4276665" conceptname="Feels cold">coldness</span> and <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span> of the digits may occur. If the condition is allowed to progress untreated, <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">gangrene</span> can result.</p>
<p>While most cases of <span class="product-label-link" type="condition" conceptid="4201303" conceptname="Ergotism">ergotism</span> associated with ergotamine treatment result from frank overdosage, some cases have involved apparent <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>. There are few reports of <span class="product-label-link" type="condition" conceptid="4201303" conceptname="Ergotism">ergotism</span> among patients taking doses within the recommended limits or for brief periods of time. In rare instances, patients, particularly those who have used the medication indiscriminately over long periods of time, may display withdrawal symptoms consisting of rebound <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> upon discontinuation of the drug.</p>
<p>Rare cases of solitary rectal or <span class="product-label-link" type="condition" conceptid="444397" conceptname="Ulcer of anus">anal ulcer</span> have occurred from abuse of ergotamine suppositories usually in higher than recommended doses or with continual use at the recommended dose for many years. Spontaneous healing occurs within usually 4-8 weeks after drug withdrawal.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.2"></a><p></p>
<h2><span class="Bold">Information for Patients</span></h2>
<p class="First">Patients should be advised that two tablets of ergotamine tartrate and caffeine should be taken at the first sign of a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span>. No more than 6 tablets should be taken for any single <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attack. No more than 10 tablets should be taken during any 7-day period. Administration of ergotamine tartrate and caffeine tablets should not exceed the dosing guidelines and should be used for chronic daily administration (see <a href="#s28">DOSAGE AND ADMINISTRATION</a>). Ergotamine tartrate and caffeine should be used only for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span>. It is not effective for other types of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> and it lacks analgesic properties. Patients should be advised to report to the physician immediately any of the following: <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> in the fingers and toes, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span> in the arms and legs, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in the legs, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the chest or temporary speeding or slowing of the heart rate, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="_Drug_Interactions"></a><a name="section-7.3"></a><p></p>
<h2><span class="Bold">Drug Interactions</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.1"></a><p></p>
<h3>
<span class="Bold">CYP 3A4 Inhibitors (e.g. </span><span class="Bold">Macrolide</span><span class="Bold"> Antibiotics and Protease Inhibitors)</span>
</h3>
<p class="First">See <a href="#s9">CONTRAINDICATIONS</a> and <a href="#s10">WARNINGS</a>.</p>
<p>Ergotamine tartrate and caffeine should not be administered with other vasoconstrictors. Use with sympathominetics (pressor agents) may cause extreme elevation of blood pressure. The beta-blocker Inderal (propranolol) has been reported to potentiate the vasoconstrictive action of ergotamine tartrate and caffeine by blocking the vasodilating property of epinephrine. Nicotine may provoke <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span> in some patients, predisposing to a greater ischemic response to ergot therapy.</p>
<p>The blood levels of ergotamine-containing drugs are reported to be elevated by the concomitant administration of macrolide antibiotics and vasospastic reactions have been reported with therapeutic doses of the ergotamine-containing drugs when coadministered with those antibiotics.</p>
</div>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.4"></a><p></p>
<h2><span class="Bold">Pregnancy</span></h2>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.5"></a><p></p>
<h2>
<span class="Bold">Teratogenic</span><span class="Bold"> Effects</span>
</h2>
<p class="First">Pregnancy Category X: There are no studies on the placental transfer or <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> of the combined products of ergotamine tartrate and caffeine. Caffeine is known to cross the placenta and has been shown to be teratogenic in animals. Ergotamine crosses the placenta in small amounts, although it does not appear to be embryotoxic in this quantity. However, prolonged <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span> of the uterine vessels and/or increased myometrial tone leading to reduced myometrial and placental blood flow may have contributed to <span class="product-label-link" type="condition" conceptid="80204" conceptname="Fetal growth restriction">fetal growth retardation</span> observed in animals (see <a href="#s9">CONTRAINDICATIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="section-7.6"></a><p></p>
<h2>
<span class="Bold">Nonteratogenic</span><span class="Bold"> Effects</span>
</h2>
<p class="First">Ergotamine tartrate and caffeine is contraindicated in pregnancy due to the oxytocic effects of ergotamine (see <a href="#s9">CONTRAINDICATIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-7.7"></a><p></p>
<h2><span class="Bold">Labor and Delivery</span></h2>
<p class="First">Ergotamine tartrate and caffeine is contraindicated in labor and delivery due to its oxytocic effect which is maximal in the third trimester (see <a href="#s9">CONTRAINDICATIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.8"></a><p></p>
<h2><span class="Bold">Nursing Mothers</span></h2>
<p class="First">Ergot drugs are known to inhibit prolactin but there are no reports of decreased lactation with ergotamine tartrate and caffeine. Ergotamine is excreted in breast milk and may cause symptoms of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, weak pulse and unstable blood pressure in nursing infants. Because of the potential for serious adverse reactions in nursing infants from ergotamine tartrate and caffeine, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.9"></a><p></p>
<h2><span class="Bold">Pediatric Use</span></h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1><span class="Bold">ADVERSE REACTIONS:</span></h1>
<p class="First">Cardiovascular: Vasoconstrictive complications of a serious nature may occur at times. These include <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, absence of pulse, <span class="product-label-link" type="condition" conceptid="4035643" conceptname="Cold extremities">cold extremities</span>, <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">gangrene</span>, precordial distress and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, EKG changes and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pains</span>. Although these effects occur most commonly with long-term therapy at relatively high doses, they have also been reported with short-term or normal doses. Other cardiovascular adverse effects include transient <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> or <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>.</p>
<p>Gastrointestinal: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>; rectal or <span class="product-label-link" type="condition" conceptid="444397" conceptname="Ulcer of anus">anal ulcer</span> (from overuse of suppositories).</p>
<p>Neurological: <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, and <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>.</p>
<p>Allergic: <span class="product-label-link" type="condition" conceptid="4026047" conceptname="Sacral edema">Localized edema</span> and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>.</p>
<p>Fibrotic Complications: (see <a href="#s10">WARNINGS</a>).</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-9"></a><p></p>
<h1><span class="Bold">DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></span></h1>
<p class="First">There have been reports of drug abuse and psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> in patients on ergotamine tartrate and caffeine therapy. Due to chronicity of <span class="product-label-link" type="condition" conceptid="4134454" conceptname="Vascular headache">vascular headaches</span>, it is imperative that patients be advised not to exceed recommended dosages with long-term use to avoid <span class="product-label-link" type="condition" conceptid="4201303" conceptname="Ergotism">ergotism</span> (see <a href="#_PRECAUTIONS">PRECAUTIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1><span class="Bold">OVERDOSAGE</span></h1>
<p class="First">The toxic effects of an acute overdosage of ergotamine tartrate and caffeine are due primarily to the ergotamine component. The amount of caffeine is such that its toxic effects will be overshadowed by those of ergotamine. Symptoms include <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span> of the extremities associated with diminished or absent peripheral pulses, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span> and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>. A case has been reported of reversible bilateral <span class="product-label-link" type="condition" conceptid="435269" conceptname="Optic papillitis">papillitis</span> with ring scotomata in a patient who received five times the recommended daily adult dose over a period of 14 days.</p>
<p>Treatment consists of removal of the offending drug by induction of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>. Maintenance of adequate pulmonary ventilation, correction of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and control of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and blood pressure are important considerations. Treatment of peripheral <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> should consist of warmth, but not heat, and protection of the ischemic limbs. Vasodilators may be beneficial but caution must be exercised to avoid aggravating an already existent <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="_DOSAGE_AND_ADMINISTRATION"></a><a name="section-11"></a><p></p>
<h1><span class="Bold">DOSAGE AND ADMINISTRATION</span></h1>
<p class="First">Procedure: For the best results, dosage should start at the first sign of an attack.</p>
<p>Adults: Take 2 tablets at the start of attack; 1 additional tablet every Â½ hour, if needed for full relief (maximum 6 tablets per attack, 10 per week).</p>
<p>Early Administration Gives Maximum Effectiveness.</p>
<p>Maximum Adult Dosage: Six tablets is the maximum dose for an individual attack.</p>
<p>Total weekly dosage should not exceed 10 tablets. Ergotamine tartrate and caffeine-tablets should not be used for chronic daily administration.</p>
<p>In carefully selected patients, with due consideration of maximum dosage recommendations, administration of the drug at bedtime may be an appropriate short-term preventive measure.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-12"></a><p></p>
<h1><span class="Bold">HOW SUPPLIED</span></h1>
<p class="First">Ergotamine Tartrate and Caffeine Tablets USP, 1 mg/100 mg are round, film coated buff colored tablet; printed "WW 120" in black ink and are available in:</p>
<p>Bottles of 30 tablets. </p>
<p>Bottles of 100 tablets. </p>
<p>Bottles of 500 tablets. </p>
<p>Store at 20Â°-25Â°C (68Â°-77Â°F) [See USP Controlled Room Temperature].</p>
<p>Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.</p>
<p>Manufactured By:<br>West-ward Pharmaceutical Corp.<br>Eatontown, NJ 07724<br>Revised November 2004</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p>NDC 0143-2120-01<br>Ergotamine Tartrate and Caffeine<br>Tablets, USP<br>1 mg/100 mg<br>Rx Only<br>100 Tablets <br>West-ward Pharmaceuticals Corp. </p>
<p><img alt="NDC 0143-2120-01
Ergotamine Tartrate and Caffeine
Tablets, USP
1 mg/100 mg
Rx Only
100 Tablets 
West-ward Pharmaceuticals Corp. 
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=19479eeb-f507-48a8-bca3-c9cc0a0f6021&amp;name=ergotamine-tartrate-and-caffeine-01.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ERGOTAMINEÂ 		
					</strong><br><span class="contentTableReg">ergotamine tartrate and caffeine tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0143-2120</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ERGOTAMINE TARTRATE</strong> (ERGOTAMINE) </td>
<td class="formItem">ERGOTAMINE TARTRATE</td>
<td class="formItem">1Â mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>CAFFEINE</strong> (CAFFEINE) </td>
<td class="formItem">CAFFEINE</td>
<td class="formItem">100Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TARTARIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">WW;120</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0143-2120-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0143-2120-05</td>
<td class="formItem">500  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:0143-2120-30</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040510</td>
<td class="formItem">09/17/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>West-Ward Pharmaceutical Corp
							(001230762)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 4/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>2dd70d46-765d-434d-92e6-4f8974dc31af</div>
<div>Set id: 19479eeb-f507-48a8-bca3-c9cc0a0f6021</div>
<div>Version: 2</div>
<div>Effective Time: 20130410</div>
</div>
</div>Â <div class="DistributorName">West-Ward Pharmaceutical Corp</div></p>
</body></html>
